Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
@ the 12:30 min/sec mark the CEO completely dodges the actual question being asked by the interviewer with an offhand analogy. The true meaning of the question is why the hell did management wait so FN long before they went after CKD along with the existing drugs already purchased in the reverse takeover of Breathtec Biomedical? Moreau went off on a long and drawn out tangent to the point you damn couldn't remember the original question. Moreau has no good answer for why they sat on CKD. Just like he has no reasonable answer for why they rolled Chronic Cough into the IPF study in Australia. One can tell Moreau is still chomping at the bit to get back to slow bus studies in Australia versus getting to actual data readouts expeditiously. Managements incompetence shtick is way past old now and none of us are getting any younger.
Christopher J. Moreau & company wants $9 Million USD for the next capital raise.
That means they will likely dish out somewhere near 2 million shares and 2 million warrants.
They are off to a bang up job in 2022!
You can start banging your head against the wall now.
The share price will surely drop below $3 per share as a result of a 120% increase in the outstanding shares not including an additional 2 million warrants.
Pre-split shareholders will likely not have any chance at recouping losses for the next several years if ever.
Moreau the Moron has struck again!
M$
Accurate detection of THC after 15 minutes of consumption remains a work in progress based on my understanding of what Dr. Boock stated in the Texas Forum.
The device has never been in the hands of law enforcement and there is no timeline of when or if that will ever happen.
The device remains in the prototype testing mode and there will be future iterations (Beta 5, 6, 7, 8...) for the foreseeable future.
I did not hear a clear answer to whether or not the device has been tested in all weather conditions for accuracy and functionality.
I did not hear an understanding of how long after edibles are consumed before the device can detect thc in the breath.
There were many questions Dr. Boock simply did not address.
What is certain is Dr. Boock was relieved the Q&A was over.
Can't wait to see the recorded video.
Cannabix Technologies story is perilous.
M$
Yeah, more shit they left sitting on the shelf to collect dust while raping everyone to go after COVID. Yeah, add another Phase 1 and off to Australia with slow bus studies that never end to save a buck as the company careens over another man-made cliff. Keep the Phase 1 clinical studies coming! They bode well for the pending capital raise that will wrap shareholders around the axle of the short bus but good.
The only significant changes I see to managements so-called reorganization of the company this far is - You are guaranteed to get much older waiting for results, Moreau hiring his old pals at failed Miraculins, insiders will continue accumulating wealth on your time and dime.
Crazy Ch!t
M$
It's VERY FRUSTRATING explaining this over and over again here.
Look at the below chart:
Do you see where it says "Nasdaq Capital Markets"? If so, Algernon falls under those set of listing rules - not Nasdaq Global Select Market or Nasdaq Global Market. It's a 3 Tier system and once again - Algernon falls under the Nasdaq Capital Markets tier.
Now, look at the same chart. Do you see where it says "Equity Standard"? If so, Algernon falls under those standards under the Nasdaq Capital Markets requirements.
Now look at the actual requirements needed to uplist. If you can understand the list of requirements one can easily see that the only requirement that could potentially raise any concerns is where it states "Market Value of unrestricted Publicly Held Shares". Do you see that? If so, lets move forward in the understanding.
What people hefre are not understanding is an uplist will come with raising capital. Meaning, new shares will be issued at whatever set price or price the market will bear. Those additional shares will count towards the Market Value Of Unrestricted Publicly Held Shares.
As of right now with the current outstanding shares of 1,674,868, to get to a $15 million valuation the current shares would need to be listed at Nasdaq at $9 USD per share.
In any event, the uplist requirements for the share price are not backwards looking. It's a myth about the stock having needed to trade x number of days or months prior to an uplist. The uplist requirements/share price is set AT THE TIME OF THE UPLIST.
Therefore, Algernon meets all the requirements of Nasdaq Capital Markets as they have told the market in written form and Moreau stating it to all in the last Q&A webcast. The question was directly posed to him and he answered it in the affirmative by stating the company and its accountants and attorneys are confident they meet all the uplist requirements.
However, people will continue to read and understand whatever it is they think or believe is correct even though they themselves have no understanding of the uplist and still want to question others with a better understanding. Pennyland is as Pennyland does.
I do believe in this case I had the ignore button active, but my days here are coming fast to a close. I'm feeling sentimental.
peace,
M$
The dilution will happen whether AP get's up-listed or not if they plan to execute anything moving forward. Whether or not $5 (5 Cent pre-split price) is the offer price has yet to be determined - but given managements history of fire sale Private Placements what do you truly think management will do? Everything in the pipeline is now at the preclinical trial phase. So much for a Phase 2 Chronic Cough study anytime in the near future. They are telling you one thing and doing another on paper. You are getting two different stories (verbal/written) and left to sift through the weeds to figure out what's the truth. Yet, there are people here that will swear up and down the individual shareholder is suppose to make sense of it all and their losses are all their fault. Yeah, WFT ever. Red Hot pitchforks is too good for the sh!t management has pulled over the past 3+ years.
M$
The listing requirements have been posted here. Algernon meets the primary requirements as written by Nasdaq. However, it's my belief Nasdaq makes judgement calls based on their overall opinion of a company. Character could well play a part if or when Algernon gets the go-ahead by Nasdaq.
M$
Fam/Friends/Insiders burned? LMAO
M$
It took less than 2.5 years (Nov 2018 to March 2021) for Christopher J. Moreau (CEO) to dilute Algernon Pharmaceuticals 6 Times Over from 20+ Million share outstanding to 160+ Million shares outstanding, not including warrants. At $5 per share post "consolidation" (reverse split of 100 shares to 1 share) the next capital raise will likely be a 5 Times Over dilution scheme in one fell swoop. That's assuming the "CEO" is going to go after at least half of the 50 Million dollar Shelf Prospectus sitting on the table. Moreau will have diluted the company at least 10 Times Over before ever getting to a real world stat sig clinical trial. What has truly happened with the "reorganization" of the company is they have burned down the past with all pre-consolidation shareholders locked inside the building. The plan moving forward is nothing like what management sold to would be shareholders the past several years. Algernon is not a Phase 2 clinical trial company or fast track Repurposed Drugs company. We have witnessed the slow and ineffective shoestring budget strategy employed by management that does not appear to have changed as part of the reorganization plan. Hence, dilution will remain a central part of managements strategy moving forward if not backwards.
Here is the new look of the clinical trial pipeline:
Candidate Indication Development Stage
Inflammatory disorders
NP-120 Idiopathic Pulmonary Fibrosis & Chronic Cough Preclinical
NP-251 Chronic Kidney Disease Preclinical
Cerebrovascular disorders
AP-188 Stroke Preclinical
Oncology
NP-120 Pancreatic Cancer Preclinical
NP-120 Small Cell Lung Cancer Preclinical
* In addition to the above, the Company is considering repurposing additional drug candidates currently in the preclinical stage
^ THE ABOVE PRECLINICAL INFORMATION IS ON PAGE 7 - "PROSPECTUS SUMMARY"
www.otcmarkets.com/filing/html?id=15587003&guid=nSWwk67MdXhEY0h
Here is Algernon Pharmaceuticals latest timeline to start a Phase 2 clinical trial & timeline to complete a Phase 2 clinical trial:
^ The above chart shows the start of a Phase 2 clinical trial in mid 2023 & the completion of a Phase 2 clinical trial at the end of 2025/beginning of 2026.
If the above timelines were to hold without delay you could expect the first (1st) official Phase 2 data readout powered for statistical significance sometime around Q2 2026.
THAT IS 4.5 YEARS FROM NOW BEFORE THE 1st PHASE 2 DATA READOUT @ ALGERNON PHARMACEUTICALS.
Algernon Pharmaceuticals reorganization plan and timeline cannot and will not remain a part of my portfolio.
Thanks for the due diligence Shell3.
Peace,
M$
The Art Of Psychedelic Messaging To The Masses
Short Interest in Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Expands By 150.0%
February 15, 2022 ETF Daily News Team
Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) was the target of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 500 shares, a growth of 150.0% from the January 15th total of 200 shares. Based on an average daily volume of 14,400 shares, the days-to-cover ratio is presently 0.0 days.
Algernon Pharmaceuticals stock opened at $5.23 on Tuesday. Algernon Pharmaceuticals has a twelve month low of $2.50 and a twelve month high of $32.50. The company’s 50-day moving average price is $4.95 and its 200-day moving average price is $5.99.
https://etfdailynews.com/news/short-interest-in-algernon-pharmaceuticals-inc-otcmktsagnpf-expands-by-150-0/
$32.50 to $2.50 is a 92% drop in stock price. Moreau drives the pennyland bus around with less than a tenth of gas in the tank. An utterly pathetic one year performance @ Algernon Pharmaceuticals Inc. What's likely worse is a pending Private Placement in the very low range of the $32.50 to $2.50 USD. We will see shortly Moreau's full circle of life with his leadership at AP. Is he a Lion ready to roar or content with being a snake in the grass like Malhi. The word is Moreau is no longer under the influence of the DUI guy even though DUI guy still controls millions of AGN shares + warrants to match. Therefore, we will see if Moreau's soul truly bears any fruit.
No More Should You Eat From The Manchineel Tree
M$
Revised/Corrected Link to Psychedelic Sector round Table:
By Far The Best Roundup of Psychedelic Sector CEOs' To Date.
It's worth a watch to get a gauge of where the industry as a whole is headed in the future and the challenges ahead.
Elevator Music while waiting for the obvious @ AP :
DMT Phase 1 & Nasdaq Listing & Capital Raise Numbers
6 6 6 ~ Go Figure
$6.66 -0.04 | -0.60% Bid: 6.67 x 500 Ask: 6.95 x 500 Volume: 362
CAD | CANADIAN SECURITIES EXCHANGE | DELAYED PRICE
FEBRUARY 11, 2022 9:35 AM EST
M$
I'll agree with the science fiction part because I honestly have zero idea where you're going with this story but I do know I'm not going to further entertain it. So I'll close my curtains and exit the stage with this:
Corey Kent is not simply an "Office Manager". He's an Office Management Partner. The emphasis being on PARTNER. As in having an ownership stake in the company and damn near could be the CEO on the ladder.
mcmillan.ca/people/cory-kent/
IMO, it's completely irrelevant here.
peace,
M$
Encore
Location: 1055 West Georgia Street
Vancouver, British Columbia
Algernon moved into a high rise building that also houses McMillan. We get it. What I don't get is what does McMillan have to do with Algernon? What does an employee of McMillan named Cory Kent have to do with Algernon? Should we now be doing due diligence about a law firm? It just doesn't make any sense to me. Please provide further information regarding your latest McMillan post. Thank you.
earth.google.com/web/search/1055+West+Georgia+Street,+Vancouver,+BC,+Canada/@49.285265,-123.1216604,114.00904905a,660.44779434d,35y,0h,45t,0r/data=CpoBGnASagolMHg1NDg2NzE4MWEyNDAwMDAxOjB4NmNhODVkZTMyOWFkNWZlNBnC2EKQg6RIQCH4zbNIycdewCovMTA1NSBXZXN0IEdlb3JnaWEgU3RyZWV0LCBWYW5jb3V2ZXIsIEJDLCBDYW5hZGEYAiABIiYKJAm-7GiIWoRJQBEQSrTjzIJJQBlK2CAvQ4JcwCEFcc5PxoRcwCgC
M$
I'm sorry to read you are siding with nonsense.
No way in hell is the Cannabix FAIMS tech not the same FAIMS tech as what Breathtec shareholders paid for 50/50 with Cannabix. It's not possible! If anything Breathtec and Cannabix should be sued for that BS they pulled on Btec shareholders. The statue of limitations surely has not run it's course. It's the same tech - from the same lab - done by the same people - that being the Breath Collection contraption that looks like a bulky hair dryer and that Black Box.
peace,
M$
ARK’s Cathie Wood Is Bullish On Psychedelics Stock
thedalesreport.com/psychedelics/cybin-announces-u-s-patent-grant-for-deuterated-dmt-to-treat-anxiety/
Yo Shell. Let me ask you a couple of straight up questions.
In the time you have spent here did at anytime you think the FAIMS breathalyzer would be scrapped in the manner in which it was by the incoming CEO?
If your answer is no...can you please tell me how someone would hedge a bet against something like that happening?
I mean, surely you could own Cannabix as well, but I'm talking about purely from the perspective of a shareholder who did their due diligence. Read all the filings and followed what the CEO stated as the FAIMS device was moving forward as previously planned.
However, we all know that is not what played out.
How does someone reconcile that...by tucking tail and running or blaming yourself for what appeared to be legitimate but was merely an act of underhanded selfishness for another person (King Cobra) and company (Cannabix)?
Shell JMO -
It's great advice for the youth/newbies. Meanwhile, old people like you and me will rifle off negative numbers, call out King Cobra, and Lord willing live to fight another day. I do what I do not out of hate or failure. I do what I do because IF I DON'T no one else here will.
My best guess is if I wasn't posting here someone else would be here daily to flip numbers inside out and backwards to get to a negative number by any means necessary. I've seen that here year on end in the days of Breathtec Biomedical.
Volume is nil. So no one is selling. Which also means no one is buying the sh!t either. Go figure!
Thank you Shell for the blast from the past motivation.
peace,
M$
Yo Old Man! Surely there is no debate about the timeline of the past to the present? Rhetorically speaking of course. Now go Back to the Future >>> and review beer buddies' latest video @ the 6:30 to 7:00 min/sec mark.
What I interpret the "CEO" as saying is that the launch of any Phase I cancer trial(s) in 2022 remains up in the air like a thought bubble.
Here’s what the Interviewer said about the cancer research @ Algernon Pharmaceuticals (AP):
Regarding Nasdaq aspirations, HQ likely needed to break all paper trail ties to the former Bookkeeper/CFO (Michael Sadhra) and right hand man of King Cobra. So they found another warehouse to hideout. Who knows if the rent payments went up or down... Good catch.
Thx.
M$
Another A-typical line about someone trying to short a junk stock like Algernon. I never personally met anyone who ever shorted a penny stock. I'd be surprised if anyone here has either. What we do know is Algernon "acquired" a so-called pharmaceutical company named Nash Pharmaceuticals with a purpose to move forward with NASH disease clinical trials as the name implies. Scratch that one off the list. Moving forward from 2018 to 2019 to 2020 to 2021 to 2022 to 2023 to 2024 it will not be until at minimum 2024 Algernon will have it's 1st Data Readout powered for statistical significance. Look back at hose previous years and ask what has truly been accomplished based on that "Repurposed Drugs" chart Moron & Company peddled to the public as a fast track to getting to Phase III clinical trials. As of today there are only going to be Phase 1 clinical trials coming out of Algernon's pipeline. There will not be a Phase II launch of DMT in 2022. You can bet on that because none of Algfernon's timelines meet their stated goals. Even as of today having watched Morons latest webcast video he stated being "hopeful" Algernon will start at least one Phase I clinical trail for cancer. He's already beginning to walk back what's written in the Corporate Summary. What we also know is Moron went out and hired his old gang from Miraculins which appeared to be nothing more than a dilution machine for a failed medical device they peddled for 20 years. Interesting how Moron landed the job at Breathtec Biomedical, a so-called medical device company, and one of the first things he accomplished was scrapping the FAIMS device and agreement with absolutely Zero to show for it's work along side Cannabix. Cannabix now has the device Breathtec billed as a Point Of Care (POC) device intended for research purposes. That very device is under another name at Cannabix. Talk about getting the royal shaft. Moron has done the complete bidding of the devil from day one at Algernon. To date, the company has been consolidated and you can be rest assured he will dilute the hell out of Algernon moving forward. He, along with the insiders own very little of the company percentage wise and I'd bet they have no intentions of letting the company fly like an eagle until they have put the majority of the company shares into the hands of family and friends plan,. The consolidation gives them the easy path to accomplish that under the Shelf Prospectus of 50 Million $ CAD. If you are holding long shares the only strategy moving forward is finding the exit if you can ever break even. Breaking even does not include the many many years your money sat with management and rotted on the vine without interest. Everything about those people at HQ says amateur hour and how the Nasdaq market will view Algernon's management team remains a disturbing question. Surely, analysts will gauge the "strengths" and weaknesses of managements business model and business acumen/competence. If they delve into Morons past we all could be in deep deep sh!t for the foreseeable future if not already as we have been in the past and present. Yes, my outlook is Pessimistic based on Past Performance of People at Algernon. Throw in a couple more P's with that last sentence by adding in the Private Placements Past and Pending. As I said, Moreau's latest webcast video sets the stage for another walked back disappointment in 2022. Dilution is the #1 thing that will take place in 2022. All the other stuff is just what's necessary to make a good showing. Find your exit >>> I will and I will leave quietly.
HQ quietly released another revisionist history webcast by the CEO @ Algernon Pharmaceuticals. Such as the statement about Algernon always wanting multiple clinical trials going all at once for "multiple shots at goal". Yeah, that's not a tagline anyone hasn't heard before. The problem with it it look at the track record. The multiple shots at goal was never stated to be Phase I clinical studies or the belief any Phase II study would merely be a steppingstone to running another Phase II clinical study if some "signal" was found worthy of moving forward. Moron has ran game on shareholders with both his mouths taking in two different languages. Then he finds the most opportune time to walk back all his nonsense when the shares have been depressed and you're stuck in a losing position. I have no doubt he will continue to do the same thing. His pattern of communications with shareholders can/will never change. It's ingrained from his prior decade of running a failed medical device company into the ground.
Moron's Latest Garbage Pennyland Video Here:
Yeah, I see it posted and I raise you mine. Surely, you've made a boat load of money flipping Algernon and previous Breathtec My guess is you picked up some scraps left behind by King Cobra. That's the only clown who made a killing here. Yeah. I'll admit it. I had no idea how incompetent management would be at it's repurposed drugs strategy. Launching Phase II studies for sh!ts and giggles wasn't something I expected. Now it's Phase I studies that dominate 2022. Yeah, their biotech acumen was definitely unsuspecting. Especially when you go back and look at all the video nonsense they told shareholders ("65% chance of success!") leading up to data for covid and subsequently IPF/CC. Right up until we were told neither study was powered to get to statistical significance. Back to Back flip flops. Yeah, one should always factor in flipping pennies based on those type of insane management skills. Surely, someone has to sing the praises of failures by management. It simply won't be me. Meanwhile, tell beer buddy to put a call in to it's Ambassador that knows POTUS to get the frigging uplist done ASAP.
M$
You asked what happens next about news we already know...dilution on steroids is what happens next.
The stories are not impacting the share price - attracting the average rabid pennyland investors mind that's glued to all things pot mining crypto and covid.
Will the uplist change the momentum...who knows? One would think it can't get any worse, but Au Contraire.
We've seen this movie before and hold onto your derriere. We need 5 times the market cap from here to break even.
Double up the share count and you're talking a 100M $ market cap to break even here for pre-split/"consolidation" shareholders.
The picture being painted going forward is like (k)night versus day between the long's and the newbies.
In other cold hard truth words - 500% upside for newbies is break even for longs. That's how far over the cliff underwater the situation has thus far become.
It will likely get much worse before and/or/if it gets any better for longs. Meanwhile, none of us are getting any younger.
One opinion.
M$
Here's my take on the following Psychedelics sector article ~
Is The Psychedelics Sector In Decline? This $30M VC Fund Says HOLD
markets.businessinsider.com/news/stocks/is-the-psychedelics-sector-in-decline-this-30m-vc-fund-says-hold-1031166985
The IPF/CC study is NOT completed. The company claims full enrollment. A Data readout is a complete study. That will not happen at least until Q2 maybe even Q3 the way shits going in Australia. COVID ain't over and it could still be used as an excuse.
Also, my understanding coming from the CEOs mouth is insiders own less than 2% of the company. Which means there's more than enough shares publicly trading to meet Nasdaq requirements.
Also, a study has already been completed. That was the bombed out COVID-19 study that drove the stock over the cliff and into the abyss. It's never recovered since. That was Algernon's 1st and full accomplishment.
Thank God It's Friday.
peace,
M$
If you take the amount of time it has taken for Alernon to enroll 20 Patients versus the amount of time it took Bellus Health to enroll 310 patients for Chronic Cough the difference is WORLDS APART
Algernon - 20 patient enrollment in 19 Months
Bellus Health - 310 patient enrolled in 9 Months
On average Bellus Health enrolled 8 patients per week
Thus, it took Bellus Health less than 3 weeks to enroll 20 patients for Chronic Cough
Bellus Health Data readout - 1 Year
Algernon Data readout - 2 Years
The CEO said Bellus Health is a pure comparison to Algernon Pharmaceuticals
Maybe, if you believe in a PARALLEL UNIVERSE
M$
Child's Play
deja vu
M$
Canada Approves Psychedelic Therapy
www.freethink.com/health/canada-approves-psychedelic-therapy
Speaking of Free Think...
Note 2 8: You know one has lost the so-called argument when one reduces it down to name calling.
What's new about that?
Nothing, I tell ya.
peace
M$
Biden to relaunch ‘cancer moonshot,’ aiming to reduce death rate, administration officials say
The president plans to announce a new initiative Wednesday to improve prevention, detection and treatment of malignancies
www.washingtonpost.com/health/2022/02/02/biden-cancer-moonshot-renewal/
Another analogy I disagree with. I disagree with your belief a thc breathalyzer can/will ultimately take the same route as a BAC breathalyzer. Science is not the same. Whatever states are passing their own non-scientific patchwork of laws it still does not address true impairment. A BAC breathalyzer has already proven beyond a reasonable doubt that .08 alcohol damages enough of your brain function to tag you with being impaired. The science for THC is all over the map for people who eat or smoke a little or a lot or anything in between. It's not a debate about the overwhelming differences between BAC and THC impairment.
Also, you state a thc breathalyzer will be a tool used by the DRE on scene. Ok...but you then claim not needing to draw blood or urine. The problem with that is in order to get to actual IMPAIRMENT for a violation of the law it will require a blood draw. I do not see such an approach as becoming mainstream for roadside use by law enforcement. It's my firm belief the primary target market is employers. Employers do not have to meet the standards for a conviction of violating a traffic law.
Employers have At Will employees who can be fired for any reason the employer has crafted as a fireable offense. There are no courtrooms to adjudicate someone who'll be fired for having smoked thc while on the clock. You believe there's no need to draw blood or urine. The problem with that is in order to get to actual IMPAIRMENT for a violation of the law it will require a blood draw - Zero Tolerance or not. I will be shocked to see if Hound actually secured a contract with law enforcement. Preferably proof of inking at least 1 big names department like New York, Boston, Chicago, LA etc etc.
As far as your finger test scenario, I've never heard of such a test. Please provide a link. The overall point here is a thc breathalyzer cannot determine impairment. Period. That is where the problem lies for the technology. What you believe is there will somehow be a general consensus among the scientific community to ignore their own research that proves a thc breathalyzer cannot measure impairment. Thus, the handful of Zero Tolerance states in the USA will clamor for a device that reads you smoked in the last 2 to 3 hours. Thus, do not pass go.
I am not the enemy here. Cannabix is running against a clock where better technology will come to the fore. A more compelling scientific narrative as Cannabix continues on with it’s parade of Beta devices 1 after another after...3…4. Surely, you get the picture because that’s all shareholders ever get. Have you ever held one of those things or laid your eyes on one personally? Yeah, they stopped the roadshows years ago. Beta 2.0 flopped with their promise of having a commercial ready device to capitalize on the market. Cannabix is now saying the exact same mumbo jumbo about Germany. All that’s old is news again. Just add some color.
The legalization of recreational marijuana in Canada was 3+ years ago. That was the same time as Cannabix's all time high share price. It’s since likely been a handful or more of known/unknown dumpster fire startups inked by your management team. I stopped counting all the slow moving train-wrecks. My best guess is the Beta prototype story will ultimately evolve or rather dissolve into some other narrative about some other newly acquired technology in the marijuana sector. Meanwhile, time keeps rolling by - Bye.
Time Is The Enemy Of Algernon Pharmaceuticals @ OTC
P.S. in the present environment a thc breathalyzer sounds good to many. However, the actual science behind it strongly suggests there needs to be a better way. Even Cannabix's own scientific advisor (Dr. Marilyn Heustis) stated the ability to detect impairment from a breathalyzer is not possible. The individual variables per individual does not fit inside of a breathalyzer box. The thc breathalyzer for now remains the only thing buzzing around for answers beyond saliva and blood. The recency of use sounds attractive but it falls short of the true mission - IMPAIRMENT. Thus, there's likely a market out there for a thc breathalyzer until better science proves it obsolete. That train is already moving down the track for impairment technology. And, the newer technology would likely be incorporated directly in vehicles along with all the standard safety features. Just like phones and crap have face recognition the technology for impairment is headed in that direction. Those with DUI's won't need to blow into anything to start a vehicle. Their face and maybe even sensory from placing your hands on the steering wheel will be in play. The point of all this being, 1st mover has the best chance at the money before a thc breathalyzer runs out of runway. If businesses become aware of better tech on the foreseeable horizon who would invest in something soon to be obsolete? Future revenue is what your current dollars represent if you are someone holding onto a dream.
Half Off Sale
Happy Flipping!
peace 3x,
M$
They have billion dollar hedge fund backers. They don't need the general public's money to build out the company. The overall point is they will IPO for multiples of what the company is likely worth. X times revs, rabid investors and the only thc breathalyzer that's been peer-reviewed. That's what billion dollar entities are targeting. Unlike BLO who parades around with pictures of a contraption said to detect thc9 but no one has ever seen it in use. That's what you get as an investor thus far coming from Camp Cannabix. The competitions device has been in the hands of many for use and it's caught on camera by the media. No fake news. Yeah, BLO is a trade. 40 cent range is usually the buy signal before the next pump. Did the stock hit the 40's before today's pump?
Like clockwork...
As I've said before, with every pump moving forward it's going to get harder to reach 1$ with repetitive news of testing testing and more testing for the foreseeable future.
peace 2x,
M$
1st mover gets the spoils That's if there's truly a market for a thc breathalyzer device that doesn't detect impairment as ALL expert scientists agree upon. IMO your analogy is way flawed about Cannabix and the other half dozen or more entities chasing after a dream. There is growing talk in the scientific community about finding completely different technology to detect actual cannabis impairment. Hence, the science is moving further away from the "recency of use" angle thus far being peddled to the public. What you should also expect is HL will IPO. That's where billion dollar investment companies backing HL will make their killing.
Meanwhile, Beta 4.0, 5.0, 6.0...
peace,
M$